Bruker Acquires Disqver Metagenomic Sequencing Platform for Blood Infections

The deal with Germany's Noscendo adds the ability to screen for more than 11,000 microbes and parasites directly from blood samples.

Bruker has acquired the Disqver clinical metagenomics platform from Germany-based Noscendo.

“The acquisition of the Disqver proprietary software and workflow platform is the latest step in our evolution as an innovative microbiology and molecular diagnostics business,” Wolfgang Pusch, president of Bruker Microbiology & Infection Diagnostics, said in a statement. “We have expanded into rapid antimicrobial susceptibility testing, hospital hygiene testing, sample-to-answer molecular diagnostics with the ELITech Genius platform, and most recently into NGS for infectious disease testing. Disqver adds additional NGS applications to our portfolio for metagenomics, and enhances our support for earlier decision-making in sepsis, bloodstream infections, and severe infections.”

In a July 15 statement, Bruker said the acquisition is not expected to be material to its 2026 financial results. Financial terms of the deal were not disclosed. Whether the deal is for the Disqver platform only or Noscendo as a whole wasn’t clear. Bruker did not immediately respond to a request for comment.

Disqver performs metagenomic next-generation sequencing (mNGS) analysis directly from cell-free DNA in blood samples, without requiring prior cultivation of a sample. The platform analyzes WGS data using proprietary bioinformatics to screen for more than 11,000 microbes and parasites, returning results in under 24 hours after a lab receives a sample.

Following the acquisition, Disqver remains available for research use only while Bruker pursues regulatory registration to offer it for diagnostic use.